AGILERA PHARMA AS: årsregnskap 2023 vs 2022
Grew 43763% on revenue, weaker earnings, fresh owner capital
approved 2024-04-16; registry 2024-07-08; journal 2024 593445
Summary
What changed
Comparing Årsregnskap 2023 with 2022 for AGILERA PHARMA AS. Revenue 663 NOK → 290.8k NOK (+43763.5%). Net result -1 200 NOK → -8.32m NOK. Equity 23.2k NOK → 49.77m NOK.
On the constructive side: revenue rose; equity strengthened; cash rose. Pressures included: operating result weakened; net result weakened.
Also worth watching: cogs fell; headcount (årsverk) changed. All figures are taken from the published annual accounts for AGILERA PHARMA AS.
At a glance
Scorecard
What improved
-
↑
Revenue rose
Operating income / revenue moved from 663 NOK to 290.8k NOK (+43763.5% YoY). Calculated
-
↑
Equity strengthened
Book equity 23.2k NOK → 49.77m NOK (equity ratio 100.0% → 31.5%). Calculated
-
↑
Cash rose
Bank deposits 23.2k NOK → 8.40m NOK (+36052.5% YoY). Calculated
-
↑
Owners injected capital
Paid-in equity rose 24.4k NOK → 49.77m NOK (+49.75m NOK). Reported fact
What deteriorated
-
↓
Operating result weakened
Operating result -1 200 NOK → -10.06m NOK (op. margin -181.0% → -3459.9%). Calculated
-
↓
Net result weakened
Net result -1 200 NOK → -8.32m NOK (net margin -181.0% → -2860.5%). Calculated
Things to notice
-
·
COGS fell
COGS / varekostnad 715.2k NOK → 2 127 NOK (-99.7% YoY). Calculated
-
·
Headcount (årsverk) changed
Reported FTEs 0 → 138. Reported fact